Citi Releases Latest Top Buy Recommendations for H-Shares
June 3, 2026 — AASTOCKS Financial News
Citi has unveiled its updated list of top buy recommendations among H-shares, underscoring prominent companies that it expects to outperform in the near term. Investors looking to tap into the Hong Kong-listed shares of mainland Chinese companies may find Citi’s selections insightful as part of their portfolio strategy.
Citi’s H-Share Top Buys and Target Prices
Below is the table of Citi’s featured top buy picks with their respective target prices (TPs):
| Stock Name | Stock Code | Target Price | Short Selling Value | Short Selling Ratio |
|---|---|---|---|---|
| Tencent Holdings Ltd. | 00700.HK | HKD 763 | $2.91 billion | 12.669% |
| AIA Group Ltd. | 01299.HK | HKD 103 | $1.01 billion | 29.461% |
| Jiangsu Hengrui Medicine | 01276.HK | HKD 134 | $215.56 million | 30.938% |
| MMG Ltd. | 01208.HK | HKD 11.2 | $62.81 million | 18.748% |
| Trip.com Group Limited | TCOM.US | USD 82 | Data not specified | Data not specified |
| China International Capital Corporation (CICC) | 03908.HK | HKD 27.66 | $13.25 million | 10.039% |
| Montage Technology Co., Ltd. | 06809.HK | HKD 305 | $346.21 million | 13.524% |
| ASM Pacific Technology | 00522.HK | HKD 180 | $47.76 million | 6.299% |
Note: The short selling data is as of June 3, 2026, 16:25 (Hong Kong Time). The Hong Kong stock quotes are delayed by at least 15 minutes.
Insights on Key Picks
-
Tencent Holdings Ltd. remains a dominant pick with a robust target price of HKD 763. The company also sees substantial short selling activity valued at $2.91 billion, yet Citi’s buy rating signals confidence in its growth potential.
-
AIA Group Ltd., a major life insurance firm, holds a solid target price of HKD 103 despite a notable short selling ratio close to 30%, indicating market players may have mixed views about its near-term volatility.
-
Jiangsu Hengrui Medicine, a leading pharmaceutical company, draws attention with a target price set at HKD 134, amidst a strong short selling ratio above 30%. Citi’s optimism reflects expected resilience in healthcare demand.
-
MMG Ltd., a global resources company, is recommended with a target price of HKD 11.2, suggesting potential upside considering its market dynamics.
Additional top picks like Montage Technology and ASM Pacific Technology also feature attractive valuations supporting future growth narratives.
Market Context and Outlook
The listing of these top buys comes amid elevated market interest in H-shares as investors assess China’s economic recovery trajectory and regulatory outlook. Despite occasional volatility caused by macroeconomic factors and sector-specific challenges—such as ongoing discussions regarding US legislation potentially affecting biotech investments—Citi maintains a positive stance on selected H-share stocks.
Recent related news highlights that biotech names like Hengrui Pharma have experienced share price declines, but analysts perceive such movements as buying opportunities, mainly due to biotech sector growth fundamentals and supportive policy expectations.
How This Affects Investors
For investors focused on the Hong Kong market and Chinese mainland enterprises, Citi’s curated list offers guidance on stocks with potential to outperform. These selections can help structure focused exposure within sectors ranging from technology, insurance, pharmaceuticals, to resources.
As always, investors are advised to conduct comprehensive due diligence and consider their individual risk tolerance when acting on analyst recommendations.
About AASTOCKS
AASTOCKS.com is a leading financial information provider for the Hong Kong and China markets, offering real-time market quotes, research, and news to help investors make informed decisions.
This article was compiled based on the automatic translation and interpretation of Citi’s H-shares research release as published on AASTOCKS on June 3, 2026. For the original report and in-depth analysis, please refer to Citi’s formal research publications.
Disclaimer: This news article is for informational purposes only and does not constitute financial advice. Investors should seek professional counsel before making investment decisions.